The cancer anorexia-cachexia syndrome: myth or reality?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Controversy exists as what constitutes the cancer anorexia-cachexia syndrome (CACS), and whether it truly is a distinct clinical disorder. In this study, we aimed to: (1) assess if CACS is a distinct clinical disorder, (2) identify the symptoms characteristic of CACS, (3) evaluate CACS impact on patient outcomes (symptom burden and survival time from referral).
Consecutive patients referred to palliative medicine were assessed by 38-symptom questionnaire. Demographics, Eastern Cooperative Oncology Group (ECOG), disease and extent, and survival were recorded. CACS, defined as anorexia plus weight loss (>10% of pre-illness weight). For analysis, patients were divided into four groups: (1) group CACS; (2) group A (only anorexia, NO >10% pre-illness weight loss); (3) group WL (weight loss >10% pre-illness weight only but NO anorexia); and (4) group N (NO weight loss >10% pre-illness weight and NO anorexia). Symptoms present in ≥5%, and patients with complete data were analyzed.
Four hundred eighty-four patients had complete data, metastatic cancer, and 26 symptoms present in ≥5%. Groups had significantly different ECOG, symptom burden, and survival. Significantly different symptom prevalence between groups: dry mouth,*early satiety,*constipation,*nausea,*taste changes,*vomiting,*dysphagia,*fatigue,*weak,*lack of energy, insomnia, dyspnea, depression, hoarseness, and anxiety. The nine symptoms with asterisk were CACS specific. Symptom Burden: CACS independently predicted greatest burden. Survival: Group N had significantly longer survival.
CACS appeared to be a distinct disorder with unique clinical characteristics in our advanced cancer population. Nine other symptoms constituted CACS. CACS independently predicted higher symptom burden. CACS absence predicted longer survival. More evidence is needed to better characterize this syndrome and generate a valid CACS consensus. A comprehensive validated CACS assessment instrument is required.
- http://www.biblegateway.com Accessed 07/2009
- Loprinzi CL, Sloan JA, Rowland KM (2003) Methodologic issues regarding cancer anorexia/cachexia trials. In: Portenoy RK, Bruera E (eds) Issues in palliative care research. Oxford University Press, Inc, New York, pp 25–40
- Bennani_Baiti N, Walsh D (2009) What is the cancer anorexia-cachexia syndrome? J R Coll Physicians Edinb 39:257–262
- Grosvenor M, Bulcavage L, Chlebowski RT (1989) Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer 63(2):330–334 CrossRef
- Strasser F, Bruera E (2002) Cancer anorexia cachexia syndrome: epidemiology, pathogenesis and assessment. In: Ripamonti C, Bruera E (eds) Gastrointestinal symptoms in advanced cancer. Oxford University, New York, pp 39–80
- Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study Group (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345–1350
- Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative caredcorrelations with food intake, metabolism, exercise capacity, and hormones. Cancer 103(10):2189–2198 CrossRef
- Perboni S, Mantvovani G, Inui A, Takimoto Y (2005) Anorexia: central and peripheral mechanisms. In: Hofbauer KG, Anker S, Inui A, Nicholson JR (eds) Pharmacotherapy of Cachexia. CRC Press, Boca Raton, pp 17–30
- Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1, 000 patients. Support Care Cancer 8(3):175–179 CrossRef
- Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF (1977) Nutritional and metabolic assessment of the hospitalized patient. J Parenter Enteral Nutr 1:11–22 CrossRef
- Bozzetti F, Mariani L (2009) Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN J Parenter Enteral Nutr 33(4):361–367 CrossRef
- Giacosa A, Frascio F, Sukkar SG et al (1997) Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italian di Nutrizione Parenterale ed Enterale 15:20–23
- Feliu J, González Barón M, Berrocal A et al (1992) Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. Am J Clin Oncol 15:436–440 CrossRef
- Fietkau R, Riepl M, Kettner H et al (1997) Supportive use of megestrol acetate in patients with head and neck cancer during radio (chemo)therapy. Eur J Cancer 33:75–79 CrossRef
- Bruera E, Neumann CM, Pituskin E, Calder K, Ball G, Hanson J (1999) Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 10(7):857–859 CrossRef
- Rowland KM Jr, Loprinzi CL, Shaw EG et al (1996) Randomized double blind placebo controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 14:135–141
- Loprinzi CL, Bernath AM, Schaid DJ et al (1994) Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology 51(Suppl 1):2–7 CrossRef
- Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491–497 CrossRef
- Glare P, Sinclair C, Downing M, Stone P, Maltoni M, Vigano A (2008) Predicting survival in patients with advanced disease. Eur J Cancer 44(8):1146–1156 CrossRef
- Evans WJ, Morley JE, Argilés J, Bales C, Baracos V et al (2008) Cachexia: a new definition. Clin Nutr 27(6):793–799 CrossRef
- Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9(10):1137–1146 CrossRef
- Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9
- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 3 85(5):365–376 CrossRef
- The cancer anorexia-cachexia syndrome: myth or reality?
Supportive Care in Cancer
Volume 18, Issue 2 , pp 265-272
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Symptom burden
- Palliative care
- Industry Sectors